IDENTIFYING A CLAIMS-BASED DEFINITION OF SATISFACTION WITH LINACLOTIDE TREATMENT AMONG PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) AND CHRONIC IDIOPATHIC CONSTIPATION (CIC)
Author(s)
Trenz H1, Wolbeck R1, Martin C1, Abel J2, Reasner D3, Fu A3, Taylor D3
1Optum, Inc., Eden Prairie, MN, USA, 2Allergan plc, Jersey City, NJ, USA, 3Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA
OBJECTIVES: This study aimed to develop and validate a claims-based definition of linaclotide treatment success based on patient-reported survey data on treatment satisfaction, over 6 months, from the Chronic Constipation and IBS-C Treatment and Outcomes Real-world Research Platform (CONTOR), a longitudinal research platform combining administrative claims and patient survey data for IBS-C and CIC patients (Abel JL et al. Am J Gastroenterol 2016;111:S257). METHODS: This retrospective analysis identified CONTOR participants aged ≥18 years with evidence of IBS-C or CIC (by patient-reported physician diagnosis, treatment or symptoms) who reported current (≤7 days before survey date) or recent (8–180 days before survey date) linaclotide use. Logistic regression models were used to determine which claims-based variables (eg medication use patterns [number of fills, days’ supply], healthcare resource use, patient characteristics and demographics) best predicted treatment success by examining concordance/discordance between the predicted satisfaction, based on claims, and patient-reported treatment satisfaction with linaclotide. RESULTS: Of 627 eligible patients identified from CONTOR (mean age 46.0 years, 94.4% female), 64.6% (n=405) reported satisfaction with linaclotide treatment. Patients who reported treatment satisfaction had significantly more linaclotide fills compared to unsatisfied patients (mean 2.2 vs 0.5, respectively; p<0.001), as well as a higher number of days’ supply of linaclotide (mean 71.5 vs 20.0 days, respectively; p<0.001). The number of linaclotide fills was the strongest predictor of patient-reported treatment satisfaction (odds ratio=1.87; p<0.0001). For a cut-off point of ≥2 linaclotide fills during the past 6 months, the satisfaction model had a sensitivity of 0.52 and a specificity of 0.89. CONCLUSIONS: A refill of a linaclotide prescription is the best claims-based method of defining patient satisfaction with linaclotide treatment, consistent with behavioural expectations.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PGI34
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Gastrointestinal Disorders